AIM ImmunoTech Recruits hVIVO For Ampligen Trial For Prophylaxis Use Against Respiratory Viruses

  • AIM ImmunoTech Inc AIM has signed a Clinical Trial Agreement with hVIVO for Phase 2a Human Challenge Trial (HCT) for intranasal Ampligen as prophylaxis against respiratory viruses.
  • The HCT will test Ampligen as a potential intranasal prophylactic using a human rhinovirus (HRV-16, a common cold virus) and influenza A virus (H3N2).
  • This antiviral study will be conducted by hVIVO, a subsidiary of Open Orphan plc.
  • The AIM-sponsored study is expected to start in Q4 2021.
  • AIM submitted a proposed protocol for the study to the Oxford Research Ethics Committee/Medicines and Healthcare Regulatory Agency. 
  • The committee met last week, and its response is expected by mid-November. 
  • Phase 2a HCT will enroll 64 participants.
  • Related: AIM ImmunoTech Plans To Evaluate Two Forms Of Ampligen In Early-COVID-19 Disease.
  • Price Action: AIM stock is up 1.54% at $1.98 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareContractsGeneralBriefsPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!